Find a trial

61 clinical trials grid list download

Body (indexed field)	Identifiant (ID)								Email
	28624	1. moderate or severe cGVHD per NIH Consensus Criteria 2. KPS score > 60%. 3. Evidence of myeloid and platelet engraftment, that is, ANC > 1.0 × 10e9/L and platelet count > 50 × 10e9/L. 4. Has not received more than 3 days/72 hours of systemic corticoster	Sebastian Wittnebel	NA	Incyte Corporate	GRAVITAS-309	Trial closed	A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)	Sebastian.Wittnebel@hubruxelles.be	2/3	2
	22646	no suitable HLA-matched sibling or unrelated donor / no prior allogeneic stem cell transplantation/ AML, ALL or MDS	Philippe Lewalle	Multiple	Kiadis Pharma	HATCY study	Trial closed	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy	philippe.lewalle@hubruxelles.be	3	3
	28584	IDH1 or IDH2 +, fit for standard chemotherapy	Sebastian Wittnebel	Acute leukemia	Hovon	HOVON 150 AML/ AMLSG 29-18	Trial open for recruitment	A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy (HOVON 150 AML/ AMLSG 29-18)	Sebastian.Wittnebel@hubruxelles.be	3	3
	29135	Presence of the FLT3 mutation	Adriano Salaroli	Acute leukemia	Hovon	HOVON 156 AML / AMLSG 28-18	Trial closed for recruitment	A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy	adriano.salaroli@hubruxelles.be	3	3
	22625	RECIST 1.1, after standard trerapy	Ahmad Hussein Awada	Multiple	Lilly	I7W-MC-JQBA	Trial closed	A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors	ahmad.awada@hubruxelles.be	1	1
	22650	vaccine, diarrhea, clostridium		Multiple	Pfizer	IJB_2672	Trial closed	A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older		3	3
	22850	Metastatic, any tumors		Solid tumors	Institut Jules Bordet	IJB_2728	Trial open for recruitment	Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention
	29771	RRMM: at least 2 prior lines of therapy with at least 2 consecutive cycles of a second or third generation immunomodulator (lenalidomide or pomalidomide), steroid (dexamethasone), proteasome inhibitor (bortezomib, carfilzoib, ixazomib) and anti-CD38 MoAb		Multiple	Sanofi-Aventis	IJB_3627	Trial open for recruitment	A First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light[1]chain amyloidosis (RRLCA)		1/2	1
	29416	Documented diagnosis of MM with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to IMiD (e.g., lenalidomide, pomalidomide) and PIs (e.g., bortezomib, carfilzomib, ixazomib) either alone or in combin	Nathalie Meuleman	Myeloma	Celyad	IMMUNICY-1	Trial closed	An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease (IMMUNICY-1 - Immunotherapy for Multiple Myeloma with HLA-UNrestrIcted allogeneic CAR T-cell therapy CYAD-211)	nathalie.meuleman@hubruxelles.be	1	1
	22655	Any line	Ahmad Hussein Awada	Solid tumors	Incyte Corporate	INCB59872-101	Trial closed	A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies	ahmad.awada@hubruxelles.be	1/2	1
	22636	Under Iclusig regimen	Philippe Lewalle	Multiple	Incyte Corporate	Incyte-30006	Trial closed	Prospective Registry of Iclusig(r) (Ponatinib) used in Clinical Practice for the Treatment of Patients with Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium	philippe.lewalle@hubruxelles.be	4	4
	22849	Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors		Solid tumors		Intervention destinée aux parents	Trial open for recruitment	L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité
	22968		Christiane Jungels	Multiple	iTeos	IO-002	Trial closed	Phase I/IIa First-In_human Study of EOS884448 in Participants with Advanced Cancers	christiane.jungels@hubruxelles.be	1/2	1
	29650	Patients with RRMM who have received at least one prior line of therapy ; for whom the treating physician has made the decision to initiate isatuximab per routine practice and independently of the purpose of the study	Nathalie Meuleman	Myeloma	Sanofi-Aventis	IONA	Trial open for recruitment	A non-interventional, multinational, observational study with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM)(OBS16577) IONA	nathalie.meuleman@hubruxelles.be	4	4